Log In Sign up
The largest database of trusted experimental protocols

Fatostatin

Manufactured by Selleck Chemicals
Visit Supplier
Sourced in United States

Fatostatin is a laboratory compound used to inhibit the enzyme fatty acid synthase (FAS). FAS is an essential enzyme involved in the synthesis of long-chain fatty acids. Fatostatin primarily functions as a research tool to study lipid metabolism and related biological processes.

Automatically generated - may contain errors

Lab products found in correlation

Fatostatin, by Merck Group (1 mentions) Tamoxifen, by Merck Group (1 mentions) Mda mb 231, by American Type Culture Collection (1 mentions) Mcf 7, by American Type Culture Collection (1 mentions) Mda mb 468, by American Type Culture Collection (1 mentions) Niraparib, by Selleck Chemicals (1 mentions) Talazoparib, by Selleck Chemicals (1 mentions) Mem neaa, by Thermo Fisher Scientific (1 mentions) Heat inactivated fbs, by Thermo Fisher Scientific (1 mentions) Gm csf, by Thermo Fisher Scientific (1 mentions) Na pyruvate, by Thermo Fisher Scientific (1 mentions) Olaparib, by Selleck Chemicals (1 mentions) Penicillin streptomycin, by Thermo Fisher Scientific (1 mentions) Glutamax, by Thermo Fisher Scientific (1 mentions) Hepes, by Thermo Fisher Scientific (1 mentions) Betulin, by Selleck Chemicals (1 mentions) Olaparib, by BioXCell (1 mentions) Be0213, by BioXCell (1 mentions) Be0089, by BioXCell (1 mentions) Be0090, by BioXCell (1 mentions)

Spelling variants of this product

Fatostatin HBr (3 citations)

6 protocols using fatostatin

1

Fasting and Fatostatin Effects on Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
All animal experiments conducted in this study were approved by the Institutional Animal Care and Use Committee (IACUC) of the Air Force Medical University of PLA in China (No. IACUC-20181204) and were performed in accordance with the Guide for the Care and Use of Laboratory Animals, 8th edition. C57BL/6J mice were housed in a pathogen-free animal facility at 22±2 ℃ under a controlled 12-h light-dark cycle. We performed the following studies with male litter FASN-2A-GLuc mice: (I) a fasting and refeeding study, in which mice were randomly split into 3 groups (n=5–6 mice/group)—the ad libitum feeding group, the fasting group (fasting for 24 h), and the refeeding group (fasting for 24 h and refeeding for 4 h); and (II) a fatostatin-administration study (n=5– 6 mice/group), in which mice were given glucose and fructose solutions (Sigma-Aldrich, St. Louis, MI, USA) and treated intraperitoneally with either corn oil (control) or fatostatin (30 mg/kg; Selleck Chemicals, Houston, TX, USA) daily for 6 days.
Li W., Zhang S., Fu X., Zhang J., Li R., Zhang H., An Q., Wang W., Tian Z., Shi C, & Nie Y. (2022). Visualization and quantification of de novo lipogenesis using a FASN-2A-GLuc mouse model. Annals of Translational Medicine, 10(18), 958.
+ Open protocol
+ Expand
2

Breast Cancer Cell Line Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols
The breast cancer cell lines MCF-7, T47D, MDA-MB-231, and MDA-MB-468 were obtained from American Type Culture Collection (ATCC). All cells were cultured at 37°C and 5% CO2. The cell lines were characterized by Genetic Testing Biotechnology Corporation using short tandem repeat (STR) markers. Tamoxifen (Sigma-Aldrich, USA) was dissolved in ethanol and ethanol was used as the vehicle control. Fatostatin (Selleck, USA) was dissolved in DMSO and DMSO was used as the vehicle control.
Liu Y., Zhang N., Zhang H., Wang L., Duan Y., Wang X., Chen T., Liang Y., Li Y., Song X., Li C., Han D., Chen B., Zhao W, & Yang Q. (2020). Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer. Drug Design, Development and Therapy, 14, 3535-3545.
+ Open protocol
+ Expand
3

Monocyte Differentiation with Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Monocytes were differentiated with 40ng/ml IL-4 (Human: R&D Systems #204-IL; Murine: PeproTech #214–14-50UG) plus 200ng/ml GM-CSF (PeproTech #315–03-50UG) or M-CSF (30ng/ml) in IMDM with GlutaMAX (Gibco #31980–030), 1mM HEPES (Life Technologies #15630080), 100 U/ml Penicillin/Streptomycin (Life Technologies #15140122), 100 mM Na-Pyruvate (Life Technologies #11360070), MEM-NEAA (Life Technologies #11140050), and 10% Heat-inactivated FBS (Thermo Fisher #10438026) for 5 days. Monocytes were differentiated in the presence of 5 μM Olaparib (Selleckchem AZD2281 #S1060), 5 μM of the STING inhibitor (H151; Invivogen #inh-h151), 5 μM Fatostatin (Selleckchem #S8284), 100 nM Niraparib (Selleckchem MK-4827 #S7625), or 10 nM Talazoparib (Selleckchem BMN 673 #S7048) during the entire 5 day differentiation. The STING agonist (Chemitek #CT-ADUS100) was used at 5uM and was added for 24 hours before collection of cells. Cells were washed and collected using ice-cold dPBS with 2mM EDTA (Ca2+/Mg2+-free) and analyzed with flow cytometry.
Mehta A.K., Cheney E.M., Hartl C.A., Pantelidou C., Oliwa M., Castrillon J.A., Lin J.R., Hurst K.E., de Oliveira Taveira M., Johnson N.T., Oldham W.M., Kalocsay M., Berberich M.J., Boswell S.A., Kothari A., Johnson S., Dillon D.A., Lipschitz M., Rodig S., Santagata S., Garber J.E., Tung N., Yélamos J., Thaxton J.E., Mittendorf E.A., Sorger P.K., Shapiro G.I, & Guerriero J.L. (2020). Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nature cancer, 2(1), 66-82.
+ Open protocol
+ Expand
4

Synthesis and Evaluation of SREBP-1 Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
A small-molecule inhibitor of SREBP-1, 1-(4-bromophenyl)-3-(pyridin-3-yl)urea, was chemically synthesized (1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.90 (d, J = 29.0 Hz, 2H), 8.58 (d, J = 2.6 Hz, 1H), 8.17 (dd, J = 4.7, 1.8 Hz, 1H), 7.98–7.87 (m, 1H), 7.43 (d, J = 2.1 Hz, 4H), 7.29 [(dd, J = 8.2, 4.7 Hz, 1H), MS m/z (M + H)+: 292.41] was also gifts from Prof. and Dr. Fan Yin in the Department of Oncology, The Second Medical Center & National Clinical Research Center of Geriatric Disease, Chinese PLA General Hospital, Beijing, China. The SREBP-1 inhibitors fatostatin (catalog number: S9785) and betulin (S4754) were purchased from Selleck Chemicals (Houston, TX, USA). The powder of SI-1, fatostatin, or betulin was prepared as described in the previous publications (31 (link)–34 (link)). HCC cells were cultured and treated with the indicated concentrations of agents, and harvested for real-time reverse transcription-quantitative polymerase chain reaction (RT-qPCR), 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, or biochemical analyses.
Zou X.Z., Hao J.F, & Zhou X.H. (2021). Inhibition of SREBP-1 Activation by a Novel Small-Molecule Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Tissue to Radiofrequency Ablation. Frontiers in Oncology, 11, 796152.
+ Open protocol
+ Expand
5

Olaparib and Anti-CSF-1R Combination Therapy

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice were treated with daily with intraperitoneal (IP) injections of the vehicle dimethyl sulfoxide (DMSO) or Olaparib (Selleckchem AZD2281# S1060) dissolved in DMSO at a final concentration of 50 mg kg−1 daily. For anti-CSF-1R treatment, mice were IP injected either with IgG2a or IgG2b isotype control to match the CSF-1R antibody used in each experiment (BioXCell #BE0089, clone 2A3; BioXCell #BE0090, clone LTF-2), or anti-CSF-1R Ab (0.525 mg/mouse, or 1.2 mg/mouse BioXCell #BE0213; clone AFS98; IgG2a) or anti-CSF-1R Ab (1.2 mg/mouse IP; a kind gift from Eli-Lilly; IgG2b) as a monotherapy or in combination with Olaparib twice a week. For CD8 depletion experiments; mice were treated twice a week either with IgG2b isotype control (0.2mg/mouse BioXCell #BE0090; clone LTF-2,) or anti-CD8 depletion antibodies (0.2mg/mouse; BioXCell #BE0117; clone YTS 169.4). In the fatostatin experiment, mice were treated with 1.2 mg/mouse anti-CSF-1R twice a week for 14 weeks then treated with 0.6 mg/mouse twice a week until endpoint. fatostatin (SelleckChem #S8284) treatment was performed as previously described64 (link) with the following modifications: mice were treated daily for 14 days with 15 mg/kg of fatostatin, followed by a 18 day break and then treated once a week until the mice reached the study endpoint.
Mehta A.K., Cheney E.M., Hartl C.A., Pantelidou C., Oliwa M., Castrillon J.A., Lin J.R., Hurst K.E., de Oliveira Taveira M., Johnson N.T., Oldham W.M., Kalocsay M., Berberich M.J., Boswell S.A., Kothari A., Johnson S., Dillon D.A., Lipschitz M., Rodig S., Santagata S., Garber J.E., Tung N., Yélamos J., Thaxton J.E., Mittendorf E.A., Sorger P.K., Shapiro G.I, & Guerriero J.L. (2020). Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nature cancer, 2(1), 66-82.
+ Open protocol
+ Expand
6

Catfish Enterocyte Isolation and Inhibitor Studies

Check if the same lab product or an alternative is used in the 5 most similar protocols
Enterocytes were isolated from yellow catfish, based on the published methods 27, 28 . Four pathway inhibitors were used, and they are TPEN (Zn 2+ chelator, Sigma, MO, USA), NAC (ROS inhibitor, Selleck, TX, USA), fatostatin (SREBP1 inhibitor, Selleck, TX, USA) and STF-083010 (IRE1 inhibitor, Selleck, TX, USA). other in vitro studies. 9, [29] [30] [31] Each treatment was performed in triplicates. The cells were collected at 48 h for following analysis.
Wu K., Luo Z., Hogstrand C., Chen G.H., Wei C.C, & Li D.D. (2018). Zn Stimulates the Phospholipids Biosynthesis via the Pathways of Oxidative and Endoplasmic Reticulum Stress in the Intestine of Freshwater Teleost Yellow Catfish. Environmental science & technology, 52(16).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!